Key points are not available for this paper at this time.
Lapatinib plus capecitabine is superior to capecitabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab. (ClinicalTrials.gov number, NCT00078572 ClinicalTrials.gov.).
Geyer et al. (2006) studied this question.